Jaguar Health, Inc. (JAGX) Q3 2024 Earnings Call Transcript Summary
Jaguar Health, Inc. (JAGX) Q3 2024 Earnings Call Transcript Summary
Non-GAAP recurring The following is a summary of the Jaguar Health, Inc. (JAGX) Q3 2024 Earnings Call Transcript:
以下是捷豹健康公司（JAGX）2024年第三季度業績電話會議記錄摘要：
Financial Performance:
財務業績：
Jaguar Health reported Q3 2024 revenue of approximately $3.1 million, a 14% increase from Q2 2024 and an 11% increase from Q3 2023.
Net loss from operations decreased by $1.5 million compared to the previous year from $8.8 million in Q3 2023 to $7.3 million in Q3 2024.
Non-GAAP recurring EBITDA for Q3 2024 was a net loss of $9.2 million, worsening from a loss of $6.2 million in Q3 2023.
捷豹健康報告稱，2024年第三季度收入約爲310萬美元，較2024年第二季度增長14％，比2023年第三季度增長11％。
運營淨虧損與去年同期相比減少了150萬美元，從2023年第三季度的880萬美元降至2024年第三季度的730萬美元。
2024年第三季度的非公認會計准則經常性息稅折舊攤銷前利潤淨虧損920萬美元，較2023年第三季度的620萬美元虧損有所惡化。
Business Progress:
業務進展：
Launched FDA-approved oral mucositis prescription product, Gelclair, expanding Jaguar's commercialized products.
Achieved significant milestones in clinical development, particularly with the OnTarget Phase III trial in breast and lung cancer patients.
Continued progress with crofelemer for rare diseases, focusing on two Phase II trials for congenital diarrheal disorders and short bowel syndrome with intestinal failure.
推出經美國食品藥品管理局批准的口腔粘膜炎處方產品Gelclair，擴展了捷豹的商業化產品。
在臨床開發方面取得了重要的里程碑，尤其是針對乳腺癌和肺癌患者的OnTarget III期試驗。
crofelemer在罕見疾病方面的持續進展，重點是針對先天性腹瀉疾病和伴有腸衰竭的短腸綜合徵的兩項二期試驗。
Opportunities:
機會：
Entered the supportive care market for cancer treatment side effects with new products like Gelclair for oral mucositis, addressing significant unmet medical needs.
Potential revenue growth through clinical trials in Europe and the MENA regions for microvillus inclusion disease and short bowel syndrome.
憑藉治療口腔粘膜炎的Gelclair等新產品進入癌症治療副作用的支持性護理市場，解決了大量未滿足的醫療需求。
通過在歐洲和中東和北非地區進行微絨毛包涵體病和短腸綜合徵的臨床試驗，潛在的收入增長。
Risks:
風險：
Financial performance shows increasing losses year-over-year, highlighting challenges in reaching profitability.
Clinical trials, particularly for cancer therapy-related diarrhea, face uncertainties in achieving primary endpoints, which may impact regulatory approval and market acceptance.
財務表現顯示虧損同比增加，凸顯了在實現盈利方面面臨的挑戰。
臨床試驗，尤其是針對癌症療法相關腹瀉的臨床試驗，在實現主要終點方面面臨不確定性，這可能會影響監管機構的批准和市場接受度。
Tips: This article is generated by AI. The accuracy of the content can not be fully guaranteed. For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：本文由 AI 生成。無法完全保證內容的準確性。欲了解更多詳情，請訪問投資者關係網站。本文僅供投資者參考，不構成任何投資建議。
